These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24839254)

  • 21. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.
    Hedegger K; Algül H; Lesina M; Blutke A; Schmid RM; Schneider MR; Dahlhoff M
    Mol Oncol; 2020 Aug; 14(8):1653-1669. PubMed ID: 32335999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of Muc4 and ErbB2 in a transgenic mouse model of gallbladder carcinoma: potential pathobiological implications.
    Miyahara N; Shoda J; Kawamoto T; Ishida H; Ueda T; Akimoto Y; Kawakami H; Irimura T
    Oncol Rep; 2014 Nov; 32(5):1796-802. PubMed ID: 25174601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.
    Guo W; Pylayeva Y; Pepe A; Yoshioka T; Muller WJ; Inghirami G; Giancotti FG
    Cell; 2006 Aug; 126(3):489-502. PubMed ID: 16901783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
    Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
    Kiguchi K; Kitamura T; Moore T; Rumi M; Chang HC; Treece D; Ruffino L; Connolly K; DiGiovanni J
    Cancer Prev Res (Phila); 2010 Aug; 3(8):940-52. PubMed ID: 20682802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC; Miyake T; Parsons SJ
    Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis.
    Zhou W; Jiang C; Zhan N; Lv X; Fan L; Ninu M
    J Cancer Res Ther; 2018; 14(Supplement):S28-S35. PubMed ID: 29578146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
    Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
    Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer.
    Amano R; Yamada N; Doi Y; Yashiro M; Ohira M; Miwa A; Hirakawa K
    Anticancer Res; 2010 Oct; 30(10):4115-21. PubMed ID: 21036728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
    Pagano E; Calvo JC
    J Cell Biochem; 2003 Oct; 90(3):561-72. PubMed ID: 14523990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells.
    Wobus M; Kuns R; Wolf C; Horn LC; Köhler U; Sheyn I; Werness BA; Sherman LS
    Gynecol Oncol; 2001 Nov; 83(2):227-34. PubMed ID: 11606076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
    Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
    Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
    Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.